Stephen G. Patterson

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

L. Rhoda Molife, Gerhardt Attard, Peter C.C. Fong et al. · Annals of Oncology · 2009 · 184 citations

Medicine, Oncology, Pharmacology +17

Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells

Stephen G. Patterson, Sheng Wei, X Chen et al. · Oncogene · 2006 · 115 citations

Medicine, Oncology, Pharmacology +11

Deletion Polymorphism of UDP-Glucuronosyltransferase 2B17 and Risk of Prostate Cancer in African American and Caucasian Men

Jong-Hak Park, Lan Chen, Luke Ratnashinge et al. · Cancer Epidemiology Biomarkers & Prevention · 2006 · 107 citations · Full text

Medicine, Genetics, Urology +15

ASP85TYR POLYMORPHISM IN THE UDP-GLUCURONOSYLTRANSFERASE (UGT) 2B15 GENE AND THE RISK OF PROSTATE CANCER

Jong Moon Park, Lan Chen, Kristin Shade et al. · The Journal of Urology · 2004 · 75 citations

Life Sciences, Genetics, Molecular Genetics +10

Cognitive impairment in men treated with luteinizing hormone–releasing hormone agonists for prostate cancer: a controlled comparison

Heather Jim, Brent J. Small, Stephen G. Patterson et al. · Supportive Care in Cancer · 2009 · 34 citations · Full text

Medicine, Endocrinology, Oncology +16